Effect of Vitamin D in Rhinosinusitis with Nasal Polyps

Effect of oral Vitamin D Supplementation in recovery of the Patients with Chronic Rhinosinusitis with Nasal Polyps and Vitamin D insufficiency

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200729048247N1

Enrollment

Registered

2020-09-14

Start date

2020-08-03

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal polyps / Chronic rhinosinusitis. Nasal polyp / Chronic rhinosinusitis / vitamin D

Interventions

Intervention 1: Intervention group: treatment of vitamin D insufficiency with pearl 50000 u vitamin D per week until 8 weeks per oral(Produced by Zahravi Company). Intervention 2: Control group: plac

Eligibility

Sex/Gender

All

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: Chronic rhinosinusitis diagnosed Existence of nasal polyps on examination Vitamin D insufficiency documented in laboratory findings Conscious consent to study

Exclusion criteria

Exclusion criteria: Use of systemic corticosteroids or other immunosuppressive drugs pregnancy Age less than 10 years Existence of immunological, renal, digestive, glandular and musculoskeletal disorders such as rheumatoid arthritis, immunodeficiency, cystic fibrosis, ciliary dyskinesia, malabsorption

Design outcomes

Primary

Measure	Time frame
Improvement of disease grade. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Endoscopy before starting study and 8 weeks after starting treatment protocol.	—

Secondary

Measure	Time frame
Serum level of vitamin D. Timepoint: Measurment of serum level of vitamin D at baseline and 8 weeks after the intervention. Method of measurement: Vitamin D blood test.;Headache Improvement. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of facial pain. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of hyposmia. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Decreasing of post nasal drip. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Decreasing of rhinorrhea. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of Nasal obstruction. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of congestion. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of fever. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of Halitosis. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of Drought. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of cough. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of ear pain. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.	—

Measure

Time frame

Serum level of vitamin D. Timepoint: Measurment of serum level of vitamin D at baseline and 8 weeks after the intervention. Method of measurement: Vitamin D blood test.;Headache Improvement. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of facial pain. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of hyposmia. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Decreasing of post nasal drip. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Decreasing of rhinorrhea. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of Nasal obstruction. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of congestion. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of fever. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of Halitosis. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of Drought. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of cough. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.;Improvement of ear pain. Timepoint: Before starting the intervention and 8 weeks later. Method of measurement: Visual analogue scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Kalantari

Kashan University of Medical Sciences

Kalantari-l@kaums.ac.ir+98 31 5545 1421

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026